24/7 Market News Snapshot 23 June, 2025 – Leap Therapeutics, Inc. Common Stock (NASDAQ:LPTX)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NASDAQ:LPTX) are discussed in this article.
Leap Therapeutics, Inc. has recently captured market attention with its stock price surging to $0.508 in pre-market trading, representing a remarkable increase of 34.75% from the previous close of $0.377. The trading volume reached an impressive 12.14 million shares, reflecting heightened investor interest and a potential momentum shift. This bullish trend signals robust market confidence in Leap Therapeutics’ innovative therapies and warrants close observation from investors as the company navigates its strategic initiatives.

In conjunction with its stock performance, Leap Therapeutics has announced significant advancements in its Phase 2 DeFianCe study involving the anti-DKK1 monoclonal antibody, sirexatamab (DKN-01). The latest results highlight statistically significant improvements in progression-free survival (PFS) for patients with advanced microsatellite stable (MSS) colorectal cancer who present high DKK1 levels. In this subset, the median PFS for those treated with sirexatamab was 9.36 months compared to 5.88 months for those in the control group, indicating a strong therapeutic response.

President and CEO Douglas E. Onsi acknowledged the contributions of patients and physicians in the clinical trials and reiterated Leap’s commitment to its goals. Nevertheless, the company has decided to wind down the DeFianCe clinical trial, coupled with a strategic re-evaluation of its operations, in response to prevailing market dynamics. This includes a projected 75% workforce reduction aimed at optimizing resources and a comprehensive review of strategic alternatives to preserve shareholder value.

As Leap Therapeutics actively seeks potential collaborations for sirexatamab and other projects, it remains devoted to advancing innovative strategies in immuno-oncology, reinforcing its mission to enhance patient care amid the challenges facing the biopharmaceutical industry.

Related news for (LPTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.